Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04555811
Title FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.